| Schedule of disaggregation by revenue source |
The following table presents the Company’s revenues disaggregated by revenue source: | | | | | | | | | | | | | | | | | | | | | | | Year Ended December 31, | | (In thousands) | | 2024 | | 2023 | | 2022 | | Screening | | | | | | | | Medicare Parts B & C | | $ | 776,155 | | | $ | 701,400 | | | $ | 545,458 | | | Commercial | | 1,118,338 | | | 992,244 | | | 743,238 | | | Other | | 209,375 | | | 171,057 | | | 136,007 | | | Total Screening | | 2,103,868 | | | 1,864,701 | | | 1,424,703 | | | Precision Oncology | | | | | | | | Medicare Parts B & C | | $ | 187,948 | | | $ | 188,689 | | | $ | 197,327 | | | Commercial | | 190,595 | | | 181,318 | | | 177,518 | | | International | | 189,092 | | | 153,277 | | | 117,738 | | | Other | | 87,364 | | | 105,826 | | | 108,905 | | | Total Precision Oncology | | 654,999 | | | 629,110 | | | 601,488 | | | COVID-19 Testing | | $ | — | | | $ | 5,955 | | | $ | 58,088 | | | Total | | $ | 2,758,867 | | | $ | 2,499,766 | | | $ | 2,084,279 | |
|